Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Readies For Glucophage Generics: Adds 600 Reps, Refiles Vanlev

Executive Summary

Bristol-Myers Squibb will expand its sales force in 2002 despite an expected $1.7 bil. drop in Glucophage revenues due to the launch of metformin generics

You may also be interested in...



Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency

Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients

Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency

Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients

Merck Re-Sets Expectations For 2002: Zocor, Prilosec Are Possible Upsides

Merck's re-calibrated projections for 2002 provide some flexibility for the company if Zocor sales continue to be strong or the launch of generic versions of Prilosec are delayed

UsernamePublicRestriction

Register

PS038991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel